Frankfurt
14.08.26 | 15:25
0,028 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,040 | 0,045 | 14.08. | |
| 0,040 | 0,045 | 14.08. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | Hemostemix Inc (2): Hemostemix names longevity trial principal investigator | 2 | Stockwatch | ||
| Mi | Hemostemix Inc.: Dr. Ernst von Schwarz, Principal Investigator of Hemostemix VesCell Longevity Clinical Trial | 907 | Newsfile | Calgary, Alberta--(Newsfile Corp. - August 12, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the appointment of Prof. Dr.... ► Artikel lesen | |
| 31.07. | Hemostemix Inc (2): Hemostemix closes $322,250 second tranche of placement | 1 | Stockwatch | ||
| 31.07. | Hemostemix Inc.: Hemostemix Closes Second Tranche of Private Placement and Obtains Extension to August 14, 2026 | 608 | Newsfile | Calgary, Alberta--(Newsfile Corp. - July 30, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed the second tranche... ► Artikel lesen | |
| 29.07. | Hemostemix Inc (2): Hemostemix drafts VesCell phase 1 trial protocol | 3 | Stockwatch | ||
| HEMOSTEMIX Aktie jetzt für 0€ handeln | |||||
| 28.07. | Hemostemix Inc.: Hemostemix' Longevity Phase I Clinical Trial Leveraging VesCell's Excellent Results | 599 | Newsfile | Calgary, Alberta--(Newsfile Corp. - July 28, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), an autologous (patient's own stem cells) regenerative... ► Artikel lesen | |
| 23.07. | Hemostemix Inc (2): Hemostemix grants options to buy 6.28 million shares | 6 | Stockwatch | ||
| 22.07. | Hemostemix Inc.: Hemostemix Grants Stock Options | 411 | Newsfile | Calgary, Alberta--(Newsfile Corp. - July 22, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock... ► Artikel lesen | |
| 09.07. | Hemostemix Inc (2): Hemostemix files commercialization application | 3 | Stockwatch | ||
| 08.07. | Hemostemix Inc.: Commercialization Application Filed by Hemostemix for the Treatment of Vascular Dementia, Angina and Pain | 544 | Newsfile | Calgary, Alberta--(Newsfile Corp. - July 8, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company"), the leading autologous (patient's own stem cells) regenerative medicine... ► Artikel lesen | |
| 26.06. | Hemostemix Inc (2): Hemostemix closes $360,000 first tranche of placement | 2 | Stockwatch | ||
| 26.06. | Hemostemix Inc.: Hemostemix Closes $360,000 First Tranche of Private Placement | 403 | Newsfile | Calgary, Alberta--(Newsfile Corp. - June 26, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has closed the first tranche... ► Artikel lesen | |
| 17.06. | Hemostemix Inc.: Hemostemix' $1,000,000 Private Placement and Update | 580 | Newsfile | Calgary, Alberta--(Newsfile Corp. - June 17, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) is pleased to announce that the Company is closing up to $1,000,000 of financing in tranches... ► Artikel lesen | |
| 09.03. | Hemostemix Inc.: Hemostemix Leadership Attending Abundance360 Summit | 521 | Newsfile | Calgary, Alberta--(Newsfile Corp. - March 9, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) today announced that Thomas Smeenk CEO and Peter Lacey, Chairman are attending the 2026... ► Artikel lesen | |
| 03.02. | Hemostemix Inc.: Hemostemix Appoints Renowned Vascular Surgeon and Principal Investigator, Dr. York Hsiang, as Business Consultant to Advance First Nations-Led Healthcare Partnerships | 313 | Newsfile | Calgary, Alberta--(Newsfile Corp. - February 3, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem cell company treating those who suffer in pain from peripheral... ► Artikel lesen | |
| 16.01. | Hemostemix Inc.: Hemostemix Receives FDA Support for Its Basket Protocol Approach | 628 | Newsfile | Calgary, Alberta--(Newsfile Corp. - January 16, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous stem cell company treating those who suffer in pain from peripheral... ► Artikel lesen | |
| 31.12.25 | Hemostemix Inc.: Hemostemix Closes $480,000 Private Placement at $0.12 per Share | 443 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 31, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (the "Company" or "Hemostemix"), an autologous stem cell company treating those who... ► Artikel lesen | |
| 23.12.25 | Hemostemix Inc.: Hemostemix Appoints Dr. David B. Alper, to Lead Multidisciplinary Physician Education in the Use of ACP-01 | 594 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), an autologous stem cell company treating those who... ► Artikel lesen | |
| 11.12.25 | Hemostemix Inc.: Hemostemix CEO Introduces Conformal Consciousness Hypothesis A = E/(hv) | 421 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) the leading autologous (patient's own) stem cell therapy company offering VesCell (ACP-01)... ► Artikel lesen | |
| 11.12.25 | Hemostemix Inc.: Hemostemix Grants Stock Options | 383 | Newsfile | Calgary, Alberta--(Newsfile Corp. - December 11, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce that in accordance with its stock... ► Artikel lesen |
1 2 3 Weiter >>
48 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 3,446 | -2,87 % | Aktien KW 32 Rekorde! Endlich. Weiter so? Überkauft? Luft nach oben? News. Mutares. Klöckner. Evotec. Knaus Tabbert. WashTec. All Stabilus. ElringKlinger. Hamborner REIT. Jost. SUSS MicroTec. Rational. Elmos Semiconductor. GFT. Bastei Lübbe. Nordex ... | Aktien - Rekorde, endlich gesehen in dieser Woche. Lange erwartet, befreites Aufspielen der Bullen. Es reichten Entspannungssignale beim Iran-Krieg durch TACO, obwohl eigentlich immer noch nichts endgültig... ► Artikel lesen | |
| QIAGEN | 37,290 | -0,98 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen nach Zahlen zum zweiten Quartal von 43 auf 47 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Die Resultate... ► Artikel lesen | |
| VALNEVA | 3,061 | -0,33 % | Valneva: EMA startet Prüfung des Lyme-Borreliose-Impfstoffs | Pfizer und Valneva haben mit ihrem gemeinsam entwickelten Lyme-Borreliose-Impfstoffkandidaten PF-07307405 einen wichtigen regulatorischen Schritt in Europa erreicht. Die Europäische Arzneimittel-Agentur... ► Artikel lesen | |
| EPIGENOMICS | 0,910 | 0,00 % | PTA-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2026 | DJ PTA-Adhoc: Epigenomics AG: Vorläufiges Halbjahresergebnis zum 30. Juni 2026
Veröffentlichung von Insiderinformationen gemäß Artikel 17 MAR Schlagwort(e): Geschäftszahlen / Halbjahr
Epigenomics... ► Artikel lesen | |
| NOVAVAX | 6,950 | -0,14 % | Novavax expects $235M-$275M in 2026 adjusted total revenue while targeting $150M-$200M in 2028 non-GAAP R&D and SG&A | ||
| STRYKER | 294,40 | +0,44 % | Stryker-Aktie: Startet über 352,65 US$ die nächste Rally? | Die Stryker-Aktie hat sich nach dem scharfen Rücksetzer aus dem Frühjahr deutlich erholt und notiert inzwischen wieder bei 345,81 US$. Damit rückt der entscheidende Widerstandsbereich um 352,65 US$... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 45,890 | -0,89 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the second quarter ended June 30, 2026. "The second quarter reflected... ► Artikel lesen | |
| CO.DON | 0,014 | -34,15 % | EQS-AFR: CO.DON AG i.l.: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: CO.DON AG i.l.
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
CO.DON AG i.l.: Vorabbekanntmachung über die... ► Artikel lesen | |
| OCUGEN | 1,162 | -0,17 % | Ocugen präsentiert spätphasige Gentherapie-Strategie für Augenerkrankungen | ||
| VERA THERAPEUTICS | 31,630 | 0,00 % | Goldman Sachs lowers Vera Therapeutics stock price target to $80 | ||
| SUMMIT THERAPEUTICS | 13,350 | 0,00 % | Could Arcus Biosciences (RCUS) and Summit Therapeutics (SMMT)'s Cancer Drug Partnership Create a New Treatment Standard? | ||
| APOGEE THERAPEUTICS | 134,56 | +0,01 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| ERASCA | 18,390 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 367,40 | +0,16 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 21,625 | -0,02 % | Biotech Stocks At 52-Week Highs - LH Rises With Genetic Testing Launch, DYN, SNDA, SLN, AMLX, | LONDON (dpa-AFX) - The following biotech stocks reached a 52-week high on July 27, 2026, driven by key catalysts including prospective clinical trial results, and the launch of new services.Dyne... ► Artikel lesen |
Das Unternehmen HEMOSTEMIX INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,028 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu HEMOSTEMIX INC finden Sie auf Wallstreet Online.